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Selection of reliable cancer biomarkers is crucial for gene expression proﬁle-based precise diagnosis of cancer type and successful
treatment. However, current studies are confronted with overﬁtting and dimensionality curse in tumor classiﬁcation and false
positives in the identiﬁcation of cancer biomarkers. Here, we developed a novel gene-ranking method based on neighborhood
rough set reduction for molecular cancer classiﬁcation based on gene expression proﬁle. Comparison with other methods such as
PAM, ClaNC, Kruskal-Wallis rank sum test, and Relief-F, our method shows that only few top-ranked genes could achieve higher
tumor classiﬁcation accuracy. Moreover, although the selected genes are not typical of known oncogenes, they are found to play a
crucialroleintheoccurrenceoftumorthroughsearchingthescientiﬁcliteratureandanalyzingproteininteractionpartners,which
may be used as candidate cancer biomarkers.
1.Introduction
DNA microarray technology, a powerful tool in functional
genome studies, has yet to be widely accepted for extract-
ing disease-relevant genes, diagnosis, and classiﬁcation of
human tumor [1–3]. Generally, genes are ranked according
to their diﬀerential expression by analysis of combination of
normal and tumor samples, and genes above a predeﬁned
threshold are considered as candidate genes for the cancer
being studied [4]. However, this method may produce a vast
number of false, positives. In addition to the false-positive
problem, the imbalance between the number of samples and
genes may potentially degrade the classiﬁcation accuracyand
it can lead to possible overﬁtting and dimensional curse or
even to be a complete failure in the analysis of microarray
data [2]. An eﬃcient way to solve these problems is gene
selection. In fact, a good gene-selection method that can
identify key tumor-related genes is of vital importance for
tumor classiﬁcation and identiﬁcation of diagnostic and
prognostic signatures for predicting therapeutic responses
[5, 6].
Identifying minimum gene subsets means discarding
most noise and redundancy in dataset to the utmost extent,
resultinginnotonlyclassiﬁcationaccuracyimprovementbut
also tumor diagnosis cost decrease in clinical application,
which is still a key challenge in gene expression proﬁle-
(GEP-) based tumor classiﬁcation. Rough set theory has
been successfully used in feature selection [7, 8]. However,
it is diﬃcult to directly and eﬀectively deal with real-valued
attributes of microarray dataset [9]. Dataset discretization
is usually adopted to tackle the problem, but the pretreat-
ment may lose some useful information. To combat this
problem, Hu et al. [10] ﬁrst presented the basic concepts
on neighborhood rough set (NRS) model and designed
a novel feature selection method called forward attribute
reduction based on neighborhood model (FARNeM) to
select a minimal reduct, which avoided the preprocess of
data discretization and hence decreased the information lost2 Journal of Biomedicine and Biotechnology
in pretreatment. But the reduct which satisﬁes criterions of
higher classiﬁcation performance and fewer gene numbers
is not unique and full of chance. Obviously, it is not
appropriate to use only a gene subset (a reduct) to train
classiﬁer, which necessitates it to select numerous minimal
gene subsets with the highest or near highest dependence on
trainingsettoavoidtheselectionbiasproblem.Breadth-First
Search (BFS) [11], a basic graph search algorithm that begins
attheroot node andexplores alltheneighboring nodes, were
adopted to implement our goals for selecting any number of
optimal and minimum gene subsets. However, for n nodes,
there are 2n combinations of gene subsets in total. It is not
p r a c t i c a lt os e a r c ha l lo ft h eg e n es u b s e t si n2 n combinations.
The computational complexity is too high. To circumvent
these problems, we proposed a breadth-ﬁrst heuristic search
algorithm based on neighborhood rough set (HBFSNRS) to
select numerous gene subsets. The dependence function of
NRS was selected as the heuristic information.
To prioritize the numerous selected genes, a parameter
sig was introduced. Previous studies showed that signiﬁcant
class predictor genes whose expression proﬁle vector show
remarkable discrimination capability among diﬀerent class
samples of speciﬁc cancer maybe play a crucial role in
the development of cancer [4]. We hypothesized that the
occurrence probability of genes in the ﬁnal selected gene
subsets may reﬂect the power of tumor classiﬁcation and
the signiﬁcance of them to some extent. To probe our
hypothesis, several publicly available microarray datasets
were applied. HBFSNRS method was also compared with
four related methods: PAM, ClaNC, Kruskal-Wallis rank
sum test (KWRST), and Relief-F to demonstrate its good
performance, eﬃciency, and eﬀectiveness in gene selection,
prioritization and cancer classiﬁcation.
2.MaterialsandMethods
2.1. The Framework of Our Analysis Method. Our proposed
method is diﬀerent from the traditional gene selection
strategies: Filters and Wrappers. The Filter methods are
based mostly on selecting genes using between-class sep-
arability criterion [12], and they do not use feedback
information from predictor performance in the process of
gene selection, such as relative entropy, information gain,
KWRST, and t-test. The wrapper methods select genes by
using a predictor performance as a criterion of gene subset
selection such as GA/SVM [13] and GA/KNN [14]. Our
method is a combination of Filter and Wrapper methods.
A novel HBFSNRS-based cancer classiﬁcation framework is
illustrated as Figure 1. Four major steps of the designed
method are described as follows.
2.2. Gene Pre-Selection Based on KWRST. All of the mi-
croarray datasets, without respect to training and test
dataset, were normalized per gene by subtracting the
minimum expression measurements and dividing by the
diﬀerence between the maximal and minimum values of that
gene. The expression levels for each gene were scaled on
[0, 1].
Gene preselection can improve the classiﬁcation perfor-
mances since it may reduce the noise, which is also the
common procedure for most classiﬁcation application [15].
We applied gene preselection on training dataset to reduce
the noise. All of the genes on the arrays of training data were
sorted according to KWRST which is suitable for multiclass
problem. In this study, the p top ranking genes (the initial
informative gene set G∗) were used for ﬁnding minimum
gene subsets for constructing ensemble tumor classiﬁer with
HBFSNRS.Generallyspeaking,morethan1%ofgenesinthe
human genome are involved in oncogenesis [16], so we set
the number of the selected top-ranked gene p = 300.
2.3. Neighborhood Rough Set Reduction. The basic concepts
of neighborhood rough set (NRS) have been introduced by
Hu et al. [10]. In our proposed algorithm, the dependence
function of NRS was introduced to evaluate the goodness
of selected gene subsets. Here, we presented only the basic
notation from NRS approach used in the paper.
Assume there are c subclasses of cancers, let D ={ d1,
d2,...,dm} denotes the class labels of m samples, where
di = k indicates the sample i being cancer k,w h e r ek =
1,2,...,c.L e tS ={ s1,s2,...s m} be a set of samples and
G∗ ={ g1,g2,...,gn} be a set of genes, the corresponding
gene expression matrix can be represented as X = (xij)m×n,
where xij is the expression level of gene gi in sample sj,
i = 1,2,...,n, j = 1,2,...,m, and usually n   m.
Given an information system for classiﬁcation learning
NDT =  S,G∗ ∪D,V, f  ,w h e r eS is a nonempty sample
set called sample space, G∗ is a nonempty set of genes also
called condition attributes to characterize the samples, D is
a set of output variable called decision attribute (class labels
of tumor samples), Va is a value domain of attribute a ∈
G∗∪D, f is an information function f : S×(G∗∪D) → V,
V =∪ a∈G∗∪D Va, a reduction is a minimal set of attributes
B ⊆ G∗.
Given for all si ∈ S and B ⊆ G∗, the neighborhood δB(si)
of si in the subspace B is deﬁned as
δB(si) =
 
sj | sj ∈ S,ΔB
 
si,sj
 
≤ δ
 
,( 1 )
where δ is the threshold and ΔB(si,sj) is the metric function
in subspace B. There are three common metric functions
that are widely used. Let s1 and s2 be two samples in n-
dimensional space G∗ ={ g1,g2,...,gn}. f(s,gi) denotes the
value xis of gi in the sample s. Then Minkowsky distance is
deﬁned as
Δp(s1,s2) =
⎛
⎝
n  
i=1
   f
 
s1,gi
 
− f
 
s2,gi
    p
⎞
⎠
1/p
,( 2 )
where (1) if p = 1, it is called Manhattan distance Δ1;( 2 )
if p = 2, it is called Euclidean distance Δ2;( 3 )i fp =∞ ,
it is called Chebychev distance. Here, we use the Manhattan
distance.
GivenaneighborhooddecisiontableNDT,X1,X2,...,Xc
are the sample subsets with decisions 1 to c, δB(xi) is the
neighborhood information granules including xi, and is
generated by gene subset B ⊂ G∗, then the lower and upperJournal of Biomedicine and Biotechnology 3
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Figure 1: The framework of our analysis method. (a) An ensemble classiﬁer was constructed on the basis of the selected genes subsets by
HBFSNRS with a speciﬁc threshold value δ. (b) Another ensemble classiﬁer was constructed based on classiﬁcation results of each δ value.
(c) sig denotes the signiﬁcance of genes, which is deﬁned as (6).
approximations of the decision D with respect to gene subset
B are, respectively, deﬁned as
LowerB(D) =
c  
i=1
LowerB(Xi),
UpperB(D) =
c  
i=1
UpperB(Xi),
(3)
where LowerB(X) ={ xi | δB(xi) ⊆ X, xi ∈ S} is the
lower approximations of the sample subset X with respect
to gene subset B, and is also called positive region denoted
by PosB(D) which is the sample set that can be classiﬁed into
oneoftheclasseswithoutuncertaintywiththegenesubsetB.
UpperB(X) ={ xi | δB(xi)∩X / =φ, xi ∈ S}denotestheupper
approximations, obviously UpperB(X) = S. The decision
boundary region of D to B is deﬁned as
BNB(D) = UpperB(D) −LowerB(D). (4)
The neighborhood model divides the samples into two
groups: positive region and boundary region. The decision
boundary is the sample set with neighborhoods from more
than one class. Through these neighborhood information,
we cannot completely be sure that these samples can be
classiﬁed into the class. The samples in diﬀerent gene
subset subspaces will have diﬀerent boundary regions and
positive regions. The size of the boundary region reﬂects
the discriminability of the classiﬁcation problem in the
corresponding subspaces. It also reﬂects the recognition
power or characterizing power of the condition attributes.
The greater the positive region is, the smaller the boundary
region will be, and the stronger the characterizing power of
the condition attributes will be. So we use the dependency
degreeofD toB tocharacterizethepoweroftheselectedgene
subsets, which is deﬁned as the ratio of consistent objects
γB(D) =
Card(PosB(D))
Card(S)
,( 5 )
where Card(S)a n dC a r d ( P o s B(D)) denotes the cardinal
number of sample set S and PosB(D),respectively. If γB(D) =
1 we say that D depends totally on B, and if γB(D) < 1, we say
that D depends partially. Here we deﬁne γ∅(D) = 0, and our
goal is to ﬁnd the gene subset B which γB(D) is equal to the
set value.
2.4. Gene Reduction Based on HBFSNRS. Informative gene
selection involves evaluating the quality of the selected gene
subsets and searching for good gene subsets quickly. Here,
the dependence function of NRS is used to measure the
goodness of the selected gene subset. Here, the computa-
tional cost problem is addressed as below.
Initially, let RED ={ { g1},{g2},...,{gp}} be a set of
gene subsets where each subset only has an informative
gene. Then, for ∀ redi ∈ RED, redi ={ gi} is
expanded to (p − 1) subsets by adding a diﬀerent genes
{gl | gl ∈ G∗,gl / ∈redi} into each redi, where we set
temporyi ={ { gig1},...,{gigi−1},{gigi+1},...,{gigp}},w e
will get p∗(p − 1) subsets in total. Among these subsets,
we select the ω top-ranked gene subsets by the dependence4 Journal of Biomedicine and Biotechnology
function that need to be expanded in the next iteration to
reconstruct the set RED, and now each element of RED has 2
genes. Similarly, in the next search layer, for ∀ redx ∈ RED,
redx ={ gigj} is extended to (p − 2) subsets excluding
the genes have listed in the redx, where we set temporyx =
{{gigjg1},...,{gigjgi−1},{gigjgi+1},...,{gigjgj−1},{gigjgj+1},
...,{gig j gp}}, i<j ,a n dw ew i l lg e tw∗(p − 2) subsets.
Among these subsets, ω top-ranked gene subsets were
selected to be expanded in next layer as the above method.
Now, the element of RED has 3 genes. The search process
continues following the above method until meeting the
stop criteria. In each layer, we expend to w∗(p − card(red))
subsets and only ω top-ranked gene subsets were selected to
reconstruct the set RED from the total subsets, so that the
search time will not increase exponentially with the increase
of search depth. Here, card(red) denotes the cardinal gene
number of the gene subset. In the virtue of the minimum
construction idea, one of the techniques for the best feature
selection could be based on choosing minimal gene subsets
that fully describe classes of tumor classiﬁcation in a given
data set. Therefore, when the maximal dependence of
the elements of RED (e.g., r Max = 0.9999) is obtained,
the increment between the maximal dependence of two
adjacent search levels is less than θ (e.g., θ = 0.0001) or
the number of iterative steps is equal to the set value Depth
(e.g., Depth = 20), the searching process ends at that
level. Otherwise, we continue to search genes in this way
until meeting the stopping criterions. The pseudocode of
HBFSNRS is shown in Algorithm 1.
The dependence function of NRS is chosen as the
objective function for evaluating the goodness of the selected
gene subset mainly because it is computationally fast in
that it does not use the feedback information of test data
in the training process. To optimize the parameter δ in
NRS that control the size of the neighborhood, diﬀerent
values for δ f r o m0t o1w i t hs t e p0 . 0 1w e r et e s t e db y
running forward attribute reduction based on neighborhood
model (FARNeM). δ values were sorted according to the
classiﬁcation accuracy by 3-KNN classiﬁer using the cor-
responding gene subset selected by FARNeM. The 5 top-
ranked δ values were used in the next step. But for ALL (a
multiclass dataset), the gene number of the selected minimal
and optimal reduct set reach 20 or even more for some of
the top ﬁve δ values. Considering that a large gene subset
with an excessive number of genes may contain much noise
and redundancy, which may bias and negatively inﬂuence
thetumorclassiﬁcationandgeneprioritization,wediscarded
such top-ranked δ values and reselected ﬁve top-ranked δ
values that produced reduct set with less than 20 genes.
2.5. Evaluation Criterion for the Selected Gene Subsets. We
adopted 3-KNN classiﬁer to evaluate the classiﬁcation per-
formance of the selected gene subsets. To improve prediction
accuracy and stability, an ensemble classiﬁer was constructed
on the basis of the selected gene subset. For each δ,a
simplemajorityvotingstrategywasappliedtointegratethew
individualclassiﬁerthatisconstructedfromtheselectedgene
subsets obtained by HBFSNRS only on training set. Then,
another ensemble classiﬁer was built based on the above
classiﬁcation results with each δ value in the similar way.
Here, we hypothesized that genes with higher occurrence
frequency are more likely to be important and cancer-related
genes. Therefore, we count the occurrence frequency of
each gene in all the selected gene subsets to measure its
signiﬁcance. But for a speciﬁc cancer, diﬀerent δ value may
selectdiﬀerentsizesoftheminimumgenesubset.Inthiscase,
only counting the occurrence frequency is not appropriate
formeasuringthesigniﬁcanceofgenes.Toavoidtheselection
bias, the signiﬁcance of genes is measured by occurrence of
probability, which is deﬁned as
sigj =
1
t
t  
i=1
fij
ni ∗ω
,( 6 )
where fij is the occurrence frequency of gene j in all the gene
subsets which are selected by HBFSNRS with δi; t is the total
number of neighborhood values (we set t = 5) ;ni is the
number of genes in a selected gene subset with δi; ω is the
number of the ﬁnal selected gene subsets by HBFSNRS (we
set ω = 500).
In order to further investigate the signiﬁcance of the
selected gene, two main methods were used: (1) the selected
genes were regarded as predictor set or classiﬁcation model;
(2) literature search and protein-protein interaction (PPI)
network analysis.
2.6. Dataset. To evaluate the performance of the proposed
method, seven gene expression datasets were used in this
study: Acute Lymphoblastic Leukemia (ALL) [17], Breast
cancer 30 (GSE5764) [18], Breast cancer 22(GSE8977) [18],
Colon cancer [19], Prostate cancer 102 [20], and Prostate
cancer 34 [21]. The two pairs of cross-platform datasets
were used to evaluate the generalization performance for
our cross-platform classiﬁcation model. Datasets of Breast
cancer, Colon cancer, and Prostate cancer are two-class
classiﬁcation systems that contain normal and tumor sam-
ples. ALL dataset is a multiple-class classiﬁcation system.
The dataset contains six subtypes of ALL: BCR-ABL, E2A-
PBX1, Hyperdip >50, MLL, T-ALL, TEL-AML1. For Breast-
cancer datasets, there are too many (54675) aﬀymetrix probe
identiﬁers, therefore the raw data were processed following
these steps: aﬀy m e t r i xp r o b ei d e n t i ﬁ e rw a sc o n v e r t e dt o
entrez identiﬁer. When multiple probes corresponded to the
same entrez ID, we averaged over these probe intensities. The
division of training set and test set is shown in Table 1.
3. Results
3.1. Redundant and Irrelevant Genes Potentially Degrade the
Classiﬁcation Accuracy. To avoid overﬁtting problem and
improve classiﬁcation accuracy and stability, an ensemble
classiﬁer was constructed on the basis of the selected
gene subsets. We observed that the ﬁnal integrated results
(Table 2) were not satisfactory and no higher classiﬁcation
accuracy obtained compared to some individual classiﬁers.
The main reason may be that our methods used all the
selected gene subsets as classiﬁcation model, which containJournal of Biomedicine and Biotechnology 5
Input  S,G,D , δ, θ, p, ω, r Max, and Depth//δ is the threshold to control the size of the neighborhood, θ is the
threshold of increment, p is the number of the preselected genes, ω is the search breadth, r Max is a given maximal
dependency function value and Depth is the upper bound of searching depth.
Output RED is the pool to contain the selected gene subsets red.
Step 1: For each gi ∈ G//Compute p-value by KWRST
Pi = KWRST(gi);
End
Step 2: gg = sort(P,“ a s c e n d ”); //Rank genes by P in ascending order
Step 3: G∗ = Select(G,gg, p); //Select he p top-ranked genes as the initial gene set G∗ by P
Step 4: For each gi ∈ G
∗//Let RED ={ { g1},{g2},...{gp}} be a set of gene subsets where each
gi → redi; //gene subset only has an informative gene.
redi → RED;
End
Step 5: iter = 1; //The times of iteration.
Step 6: For each redj ∈ RED
For each gk ∈ G∗ −redj
redj ∪ gk → RED; //Adding genes not listed in redj to redj a n ds a v ei ta se l e m e n t so fR E D
γredj∪gk(D) = Card(Posredj∪gk(D))/Card(S); //Compute dependence degree of D to redj ∪gk.
End
End
Step 7: rr = sort(r, “descending”); //Rank gene subsets byrin descending order
RED = Select(RED,rr,w); //Select ω top-ranked gene subsets to reconstruct RED.
Step 8: If (maxiter(γ) >= r Max) or abs(maxiter(r) −maxiter−1(r)) <θor (iter = Depth)
Break; //here, we deﬁne max0(r) = 0
Else
iter = iter + 1;
Go to step 6;
End
Algorithm 1: A heuristic breadth-ﬁrst search algorithm based on neighborhood rough set (HBFSNRS).
Table 1: The division of training set and test set in our experiments.
No. Dataset Training set Test set No. of gene No. of class
1 ALL 148 100 12625 6
2 Breast cancer Breast30 Breast22 19802 2
3 Colon 42 20 2000 2
4 Prostate cancer Prostate102 Prostate34 12600 2
many redundant and tumor-unrelated genes and may poten-
tially degrade the classiﬁcation performance. Figure 2 shows
the classiﬁcation accuracy with diﬀerent numbers of the top-
ranked genes sorted according to the signiﬁcance of genes
deﬁned as (6), from which we found that only a few top-
ranked genes were enough to obtain higher classiﬁcation
accuracy. Meanwhile, when more genes were used as pre-
dictor set, there was only a little increase or even decrease
in the classiﬁcation performance. Therefore, we inferred that
too many selected genes involve much more redundancy and
irrelevancy, which degrades the classiﬁcation accuracy.
3.2. Comparison with Other Related Methods. In order to
elaborate the eﬀectiveness of HBFSNRS, we compared the
accuracy of our approach with other common ﬁlter methods
including t-test, information gain, KWRST, and Relief-
F. The experimental results indicate that our method is
signiﬁcantly superior to t-test and information gain, and
slightly outperforms KWRST and Relief-F in the aspect of
tumor classiﬁcation. For simplicity, we only present KWRST
and Relief-F results here (Figure 2). We found that only a
few top-ranked genes could achieve higher accuracy in the
classiﬁcation of tumor samples of diﬀerent classes by our
proposed search algorithm. For ALL dataset, the prediction
accuracy by HBFSNRS is superior to other methods regard-
less of the much fewer genes used in cancer classiﬁcation.
For breast-cancer dataset, using one active gene could test
outcome with the accuracy of 22.73% by Relief-F, 63.64%
by KWRST, whereas 100% test accuracy was obtained using
one gene by the proposed HBFSNRS method. For colon-
cancer dataset, using one, six active genes could get the
prediction accuracy of 80% and 85% by our method, 65%,
70% by Relief-F, and 65%, 75% by KWRST, respectively. For
prostate-cancer dataset, when using more than ten genes for
tumorclassiﬁcation,KWRSTsigniﬁcantlyoutperformedour
method and Relief-F, but our method performs as well as the6 Journal of Biomedicine and Biotechnology
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Figure 2: Comparison of classiﬁcation accuracy with diﬀerent numbers of top-ranked genes on the four test datasets by HBFSNRS, Relif-F,
and KWRST.
KWRST when only using the few top-ranked genes (both of
our method and KWRST could get 97.06% accuracy using
one gene). What is more, we compared our method with
other statistical methods PAM and ClaNC. PAM, a statistical
technique for class prediction from gene expression data
that uses nearest shrunken centroids, was used to identify
class predictor genes [22]. ClaNC ranks genes by standard
t-statistics, which does not shrink centroids and uses a
class-speciﬁc gene selection procedure [23]. In our context,
ClaNC slightly outperformed PAM, so we only present the
comparison with ClaNC here (Table 3). In comparison
with ClaNC, our method could obtain higher classiﬁcationJournal of Biomedicine and Biotechnology 7
accuracy when using a few top-ranked genes. The one-gene
model by our method provides the classiﬁcation accuracy
of 100%, 80%, and 97.06% for Breast-cancer, Colon-cancer,
and Prostate-cancer dataset, respectively, whereas ClaNC
requires more genes to get the same accuracy.In ALL dataset,
the test accuracies on independent test dataset are 87% with
six genes, 94% with 12 genes, and 97% with 18 genes by our
method. Using the same six, 12, 18 active genes could test
outcomewiththeaccuracyof86%,95%,and97%byClaNC,
respectively, which indicates our method was comparable
for ALL dataset. As a comparison, the minimum genes with
the highest accuracy can be obtained in the classiﬁcation
process by HBFSNRS. In addition, results show that our
method is obviously better than ClaNC in colon-cancer and
breast-cancer cross-platform datasets. It is likely that ClaNC
is not suitable for cross-platform datasets. We proposed
that these few genes whose expression proﬁle vector showed
remarkable discrimination capability may closely correlated
to cancer and could be seen as possible disease signatures.
3.3. Analysis of the Top-Ranked Genes (Case Studies). Mining
genes that give rise to ontogenesis is one of key challenges
in the area of cancer research. Biologically the experimental
results proved that the selected genes with high classiﬁcation
accuracy are functionally related to carcinogenesis or tumor
histogenesis, so we could infer that the few top-ranked genes
may be very important for tumor diagnosis. The 10 top-
ranked genes according to the sig score for each tumor
that were regarded as the candidate cancer genes listed in
Table 4. To demonstrate our method’s ability in uncovering
known cancer genes and predicting novel cancer biomarkers,
the breast-cancer dataset was employed to this study as the
method of [24].
First, we checked whether our method can uncover
known famous cancer genes. We downloaded a list of 25
breast cancer biomarkers that have been annotated in the
OMIM database [25]. Unfortunately, our used dataset (the
300 top-ranked genes selected by KWRST) does not include
the 25 known breast cancer genes. Therefore our method
cannot be evaluated with it in terms of uncovering known
cancer genes. From another point of view, it is veriﬁed that
higher diﬀerential expression of a gene does not necessarily
reﬂectagreaterlikelihood ofthegenebeing relatedtocancer.
In other words, important genes might not be necessarily
diﬀerentially expressed. But it is undeniable that higher
diﬀerential expressions of genes are inevitably important in
the cancer diagnosis and development.
Next,literaturesearchmethodwasusedtocheckwhether
our method can predict novel cancer biomarkers. In the top
10 genes ranked by (6) for breast cancer, we found that
these genes play an important role in the occurrence of
breast cancer. The collagen triple helix repeat containing 1
(CTHRC1), ranked the ﬁrst, whose aberrant expression is
widely presented in human solid cancers including breast
cancer and seems to be associated with cancer tissue invasion
and metastasis [26] .T h eP D Za n dL I Md o m a i np r o t e i n4
(PDLIM4), ranked the second, was frequently methylated
in breast cancers but not in normal breast tissues [27]. The
keratin, type I cytoskeletal 17 (KRT17), ranked the third,
was speciﬁcally overexpressed in basal-like subtypes of breast
cancer [28]. The secreted frizzled-related protein 1 (SFRP1),
ranked the fourth, was recently found to be associated with
progression and poor prognosis in early stage of breast
cancer [29]. The collagen alpha-1 (III) chain (COL3A1),
ranked the ﬁfth, was up-regulated in both invasive ductal
and lobular carcinomas cells when compared with normal
ductal and lobular cells [30]. The peptidase inhibitor 15
(PI15), ranked the sixth, was also diﬀerentially expressed but
it was down regulated in lobular and ductal invasive breast
carcinomas [30]. The actin gamma-enteric smooth muscle
(ACTG2), ranked the seventh, is involved in the architecture
and remodeling of cytoskeleton in basal medullary breast
cancer [31]. The tissue factor pathway inhibitor 2 (TFPI2),
ranked the eighth, whose aberrant hypermethylation with
gene promoter was associated with metastasis in breast
cancer[32].TheserpinB5(SERPINB5),rankedtheninth,an
epithelial-speciﬁc serine protease inhibitor, was a biomarker
in disseminated breast-cancer cells [33].The ﬁbronectin 1
(FN1), ranked the tenth, was recently suggested to be
associated with the prognosis of patients with breast cancers
[34].
Finally, we examined gene pathway that involved by the
10 top-ranked genes. The study is carried out using the
software which can help the researchers to better under-
stand the biological phenomenon understudied by pointing
out signiﬁcant cellular functions of the selected genes
fromthewebpage“http://vortex.cs.wayne.edu/projects.htm”
[35]. Results indicate that the pathways that the 10 top-
ranked genes are involved in are ECM-receptor inter-
action (COL3A1, FN1), focal adhesion (COL3A1, FN1),
vibrio cholerae infection (ACTG2), p53 signaling pathway
(SERPINB5), Small cell lung cancer (FN1), wnt signaling
pathway (SFRP1), regulation of actin cytoskeleton (FN1),
pathways in cancer (FN1), which agree well with current
knowledge on breast cancer [36]. Thus it can be seen that
the selected genes that closely related to adhesion, motility,
and metastasis may provide new insights in the underlying
molecular mechanisms related to disease development, in
designing therapy and in prognostication for patients with
breast carcinoma. Thus, the analysis of existing biological
experiment results of breast-cancer dataset well illustrates
that our method has great power of identifying tumor-
related genes.
Furthermore, another case study for prostate-cancer
dataset was presented here. In the 10 top-ranked genes, six
of them (HPN, MAF, GSTP1, WWC1, JUNB, and RND3)
havebeen reported to be associated withprostatecancer.The
hepsin (HPN), ranked the ﬁrst, a cell surface serine protease
that is markedly up-regulated in human prostate cancer,
which is overexpression in prostate epithelium in vivo causes
disorganization of the basement membrane and promotes
primary prostate cancer progression and metastasis to liver,
lung, and bone [37]. The transcription factor (MAF), ranked
the second, was down-regulated in the tumors relative to
normal prostate tissue and may be regarded as the candidate
tumor suppressor gene [38]. The glutathione s-transferase P
(GSTP1), ranked the fourth, whose CpG island hyperme-
thylation is the most common somatic genome alteration8 Journal of Biomedicine and Biotechnology
Table 2: Classiﬁcation accuracy, sensitivity and speciﬁcity on all the test datasets by the ensemble classiﬁer.
Dataset δ value (the number of genes in the selected gene subset)
ALL 0.32(8) 0.35(9) 0.44(13) 0.47(14) 0.66(20) integration
Accuracy 89.00 92.00 93.00 94.00 93.00 95.00
Breast 0.04(2) 0.21(2) 0.29(2) 0.30(2) 0.69(3) integration
Accuracy 86.36 90.91 90.91 90.91 95.45 90.91
Sensitivity 100.00 100.00 100.00 100.00 93.33 100.00
Speciﬁcity 57.14 71.43 71.43 71.43 100.00 71.43
Colon 0.03(2) 0.04(2) 0.82(6) 0.92(3) 0.13(2) integration
Accuracy 70.00 75.00 75.00 80.00 75.00 75.00
Sensitivity 75.00 75.00 75.00 83.33 75.00 75.00
Speciﬁcity 62.50 75.00 75.00 75.00 75.00 75.00
Prostate 0.13(4) 0.20(5) 0.26(5) 0.57(5) 0.62(5) integration
Accuracy 94.12 91.18 88.24 88.24 97.06 91.18
Sensitivity 100.00 100.00 100.00 100.00 100.00 100.00
Speciﬁcity 92.00 88.00 84.00 84.00 96.00 88.00
Table 3: The comparison with the ClaNC method in classiﬁcation accuracy.
Method Number of genes selected per subclass: n (all: n ×c)
1 23456789 1 0
ClaNC
ALL(×6) 86.00 95.00 97.00 99.00 98.00 99.00 99.00 99.00 99.00 98.00
Breast(×2) 50.00 40.91 45.45 45.45 40.91 40.91 40.91 40.91 40.91 40.91
Colon(×2) 65.00 65.00 65.00 70.00 70.00 75.00 75.00 75.00 75.00 75.00
Prostate(×2) 73.53 85.29 79.41 76.47 76.47 79.41 79.41 76.47 76.47 79.41
Method Number of all genes selected
1 23468 1 2 1 8 2 4 3 0
HBFSNRS
ALL 41.00 71.00 73.00 82.00 87.00 94.00 94.00 96.00 96.00 97.00
Breast 100.00 95.45 86.36 86.36 86.36 90.91 86.36 77.27 86.36 86.36
Colon 80.00 70.00 80.00 70.00 85.00 80.00 75.00 75.00 75.00 75.00
Prostate 97.06 91.18 82.35 82.35 79.41 82.35 88.24 85.29 85.29 88.24
described for human prostate cancer [39]. The gene WWC1,
ranked the sixth, was found to interact with histone H3
via its glutamic acid-rich region and that such interaction
might play a mechanistic role in conferring an optimal
ER transactivation function as well as the proliferation of
ligand-stimulated breast-cancer cells [40]. The transcription
factor jun-B (JUNB), ranked the seventh, is an essential
upstream regulator of p16 and contributes to maintain cell
senescence that blocks malignant transformation of TAC.
JUNB thus apparently plays an important role in controlling
prostate carcinogenesis and may be a new target for cancer
prevention and therapy [41]. The Rho-related GTP-binding
proteinRhoE(RND3),rankedtheninth,arecentlydescribed
novel member of the Rho GTPases family, was regarded as
a possible antagonist of the RhoA protein that stimulates
cell cycle progression and is overexpressed in prostate cancer
[42]. The remaining genes were not identiﬁed to correlate to
prostatecancerpreviously.Thesegenesneedfurtheranalysis.
Genes related to a speciﬁc or similar disease phenotype
tend to be located in a speciﬁc neighborhood in the protein-
protein interaction network, and a protein is likely to be
coexpressed with its interaction partners and those proteins
that have similar function. Here, we applied a protein-
network-basedmethodtoanalyzetheeﬀectofneighborhood
partners on the selected genes using all interactions in the
Human Protein Reference Database [43]. Figure 3 indicates
the protein-interaction network for each top-ranked gene of
prostate cancer (KIAA0430 has no interaction partners in
HPRD). The red-ellipse nodes represent the 10 top-ranked
genes that were ranked by the sig score in (6), among which,
those with an asteroid sign means known cancer genes. The
diamondnodesindicatethedirectinteractionpartnersofthe
selected genes that were not cancer genes, and blue-octagon
nodes show those partners that are identiﬁed as known
cancer genes which were collected by querying the Memorial
Sloan Kettering computational biology website, “Oncogene”,
“tumor suppressor”, and “stability” are shown as [4, 44].
Among the 10 top-ranked genes for prostate-cancer dataset
(Figure 3), 6 genes (ABL1, JUNB, MAP, P4HB, GSTP1, and
RND3) that listed with an asteroid sign have been identiﬁed
to be known cancer genes. Here, we mainly illustrate the
three genes P4HB, PEX3, and ABL1 that we did not ﬁndJournal of Biomedicine and Biotechnology 9
Table 4: The 10 top-ranked genes selected for the four datasets.
Four datasets
ALL Breast cancer Colon cancer Prostate cancer
gene symbol sig gene symbol sig gene symbol sig gene symbol sig
LRMP 0.0801 CTHRC1 0.1212 DES 0.0895 HPN 0.174
TCFL5 0.0569 PDLIM4 0.0476 MYH9 0.0834 MAF 0.1248
CD99 0.0526 KRT17 0.0321 C3 0.062 ABL1 0.0457
MPP1 0.0483 SFRP1 0.0292 FUCA1 0.0538 GSTP1 0.0225
CD72 0.0399 COL3A1 0.0261 CSRP1 0.0427 KIAA0430 0.0216
NONO 0.0377 PI15 0.0258 MT2A 0.0421 WWC1 0.0192
DNTT 0.0345 ACTG2 0.0241 TSPAN7 0.0346 JUNB 0.0164
PLXNB2 0.0329 TFPI2 0.0217 2-Sep 0.0294 PEX3 0.0153
ECM1 0.0325 SERPINB5 0.0203 FXN 0.0236 RND3 0.0151
SMARCA4 0.0296 FN1 0.0186 PMP22 0.0214 P4HB 0.0146
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Figure 3: The protein-interaction network associated with the ten top-ranked genes for prostate cancer.10 Journal of Biomedicine and Biotechnology
reports on their association with prostate cancer. In the three
genes, P4HB and ABL1 have been known as cancer genes.
PEX3 is also a famous disease gene which was the cause
of peroxisome biogenesis disorder, complementation group
12, and zellweger syndrome. It can be seen that mutation in
these genes can lead to many diseases and may have a close
relationshipwithprostatecancer.Inthissense,ourmethodis
eﬀective on cancer-related gene selection. Recently, Aragues
et al. [4] suggest that cancer linker degree (CLD) of a protein
which was deﬁned as the number of cancer genes to which
a gene is connected is a good indicator of the probability of
being a cancer gene. We analyzed the cancer linker degree
(CLD) of 10 top-ranked genes on each of the four datasets.
For prostate cancer, as is shown in Figure 4, most of the top-
ranked genes have a direct interaction with known cancer
genesexcludingthegenePEX3,andtheCLDofABL1,JUNB,
WWC1,MAF,P4HB,GSTP1,HPN,andRND3is46,13,2,6,
7, 1, 1, and 1, respectively. In the 10 top-ranked genes of ALL
(TCFL5 and LRMP have no interaction partners in HPRD),
SMARCA4, DNTT, and NONO are known cancer genes,
and the CLD of SMARCA4, DNTT, NONO, CD72, MPP1,
and CD99 is 19, 3, 6, 1, 2, and 2, respectively. For breast
cancer, CTHRC1, PI15, and SERPINB5 have no interaction
partners in HPRD. In the remaining 7 genes of 10 top-
ranked genes, SFRP1 and TFPI2 are known cancer genes,
and SFRP1, TFPI2, FN1, COL3A1, and KRT17 have a direct
interaction with known cancer genes, the CLD of which is
2, 1, 17, 2, and 1 respectively. For colon cancer, FUCA1 has
no interaction partners in HPRD. In the remaining 9 genes,
MYH9 is a known cancer gene, the CLD of DES, MYH9, C3,
and 2-Sep is 4, 3, 1, and 1, respectively. These results show
that besides a few selected genes that typically correspond
to known speciﬁc cancer mutations, a considerable portion
of the top-ranked genes have many direct interactions with
cancer genes, which suggests that these genes should be very
likely to be involved in cancer and may play a central role in
the protein network by interconnecting many known cancer
genes, and thus the top ranked genes can be regarded as
reliable disease biomarkers.
4. DiscussionsandConclusions
4.1. Better Performance on Tumor Classiﬁcation and Gene
Selection and Prioritization. An ongoing challenge is to
identify new prognostic markers that are directly related to
disease and that can more accurately predict the likelihood
of gaining cancer in unknown samples. Results indicate
that our proposed method of gene selection by HBFSNRS
has the following advantages in trying to tack this chal-
lenge. (1) Our method could obtain the highest or near
highest prediction accuracy of tumor classiﬁcation with
the minimum gene subset. (2) Lists of ranked potential
candidate cancer biomarkers with a speciﬁc cancer are
presented by our approach. (3) Our proposed method can
obtain many optimal gene subsets in a short period of
time, which is essential to the whole search process. (4)
Compared to other gene ranking methods KWRST and
Relief-F, our method is relatively stable and contains little
chance factors. The success of our methods, gene selection
by HBFSNRS, can be attributed to a combination of several
aspects. First, we adopted the dependence function of NRS
to evaluate the goodness of selected gene subsets. There are
two main advantages for this point: time saving and tumor
classiﬁcationwithoutthefeedbackandleakedinformationof
the test dataset. Second and more importantly, the designed
process of gene search by our method can select any number
of optimal gene subsets in a comparatively short time, which
is an optimization of best-ﬁrst search. Finally, considering
the selection of δ value in the evaluation of gene subsets
has the problem that the genes with diﬀerent δ value will
have diﬀerent ranked positions or relevance to cancer. To
avoid this problem of selection bias, we deﬁned a sig score to
describethesigniﬁcanceofgenesbycombiningﬁvegroupsof
results that obtained by each δ value. We presented two case
studies on breast cancer and prostate cancer to illustrate the
power of our method to identify tumor-related genes. Our
method illustrates well its high power of tumor classiﬁcation
and gene prioritization.
4.2. Limitation and Extension. One limitation of our
approach is in data quality: current high-throughput tech-
nologies remain error prone and may be far from complete.
I nar e c e n tp a p e r ,Z h a n ge ta l .[ 45] held that the integration
o fm i c r o a r r a yd a t ag i v e su sm o r ea n a l y t i c a lp o w e ra n d
reduces the false discovery rate. Given a speciﬁc cancer,
eﬃcient ways to integrate multiple independent microarray
data may be a good way to solve the issue of data quality.
The other limitation is the optimization of the threshold
value of neighborhood rough set. On one hand, we tried the
neighborhood rough set reduction method to evaluate the
goodness of the selected gene subsets to save time in tumor
classiﬁcation without using the feedback information of the
test dataset. On the other hand, the threshold selection is
obtained through the feedback information of the test set. In
addition, diﬀerent δ values may select diﬀerent gene subsets,
hence the genes with diﬀerent δ v a l u ew i l lh a v ed i ﬀerent
positions in gene prioritization, so the selection of δ has
become more critical for gene prioritization. Fortunately, the
choice of δ is not so important for gene ranking because the
changeofgenepositionindiﬀerentδ valuesisnotsigniﬁcant.
In our study, Spearman’s rank correlation coeﬃcient was
used to determine whether there is a consistency between the
results of gene prioritization with diﬀerent δ values. Results
indicate that there is high consistency among these results.
4.3. Future Work. Our proposed HBFSNRS method has
improved the performance of tumor classiﬁcation based on
microarray and identiﬁed and prioritized lists of poten-
tial tumor-related genes from GEP, our future work will
beneﬁt further from integrating other sources. Recent
high-throughput technologies have produced vast amounts
of protein-protein interactions, which represent valuable
resources for candidate-gene prioritization and give us new
insights into the mechanism of disease. A great number of
studies have shown that integration of multiple sources of
data is more reliable for predicting cancer genes than the useJournal of Biomedicine and Biotechnology 11
ofasinglecriterion[4,46–48].Thus,itisaneﬃcientmethod
to integrate GEP and protein interaction network for gene
prioritization. Although gene expression data and protein
interaction data have been integrated for gene prioritization
[49, 50], the results are not satisfactory. Therefore, it is still a
challenging problem in the area of cancer research.
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